TR1801-ADC in Patients With Tumors That Express c-Met

Inclusion Criteria:

* Compliance with all study procedures and visits to the clinical research site
* Locally advanced or metastatic disease that is not amenable to definitive therapy
* Histologically confirmed diagnosis of a solid tumor which expresses c-Met
* Must have progressed or have been intolerant to all available therapies known to confer clinical benefit appropriate for the patient's tumor type
* Measurable baseline disease as defined by RECIST Version 1.1
* ECOG Performance Status 0-1
* Body weight within 40 and 150 kg
* Clinical laboratory values with the limits as defined by the protocol
* Not pregnant or breast feeding
* Males and women of child-bearing potential must agree to use an effective method of contraception

Exclusion Criteria:

* Any disease or condition that may be considered to pose an increased risk from study treatment or the ability of the patient to participate and comply with study procedures
* Treatment with anti-cancer therapy (including cytotoxic chemotherapy, major surgery, radiation, biologic and investigational agents) within 21 days before first dose of study treatment
* Brain metastases that has not stabilized for at least 28 days after therapy and who have discontinued steroids for \<2 weeks
* Unresolved adverse events \>= Grade 2 from prior anticancer therapies
* Acute myocardial infarction, cerebral ischemic infarct, or other arterial thrombosis within 6 months of screening for this study.
* Uncontrolled hypertension, unstable angina, or NYHA Class III/IV heart failure
* History of capillary leak syndrome
* Corticosteroid intolerance
* History of anasarca
* Untreated or uncontrolled bacterial, viral or fungal infection
* HIV infection or active infection with hepatitis B or C
* Significant liver disease
* History of alcoholism or current alcoholism
* Signs of significant portal hypertension
* Significant kidney disease within 2 years
* Active or unstable gallstone disease
* Prior treatment with a c-Met targeted agent
* Prior hypersensitivity reaction to treatment with another monoclonal antibody
* QTcF \>=470 ms
* Patients may not start any new herbal or dietary supplement within 4 weeks before initiation of study treatment nor while receiving study treatment
* Administration of a live, attenuated vaccine within 28 days before the first dose of study treatment